Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$48.51 -0.3%	$39.88	$30.04 ▼ $63.68	$4.20B	1.82	1.88 million shs	3.45 million shs
DNLI Denali Therapeutics	$13.95 -0.3%	$14.46	$10.57 ▼ $33.33	$2.03B	1.33	1.13 million shs	2.21 million shs
QGEN Qiagen	$48.19 +0.3%	$44.47	$37.63 ▼ $49.30	$10.68B	0.68	1.19 million shs	1.01 million shs
RGEN Repligen	$126.44 +1.7%	$127.70	$102.97 ▼ $182.52	$6.99B	1.11	729,171 shs	633,560 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	+2.42%	+6.78%	+34.96%	+46.77%	-9.94%
DNLI Denali Therapeutics	-0.78%	+2.72%	+6.15%	+13.83%	-39.75%
QGEN Qiagen	+0.64%	+2.89%	+6.51%	+21.68%	+20.33%
RGEN Repligen	+0.66%	+3.56%	+5.71%	-3.21%	-1.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	2.9283 of 5 stars	4.3	1.0	0.0	0.0	2.0	2.5	0.6
DNLI Denali Therapeutics	4.5328 of 5 stars	4.5	2.0	0.0	4.7	2.2	2.5	0.0
QGEN Qiagen	3.7056 of 5 stars	1.2	5.0	0.8	4.5	2.0	1.7	1.3
RGEN Repligen	4.7736 of 5 stars	4.3	2.0	0.0	4.5	2.7	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	47.91% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	141.68% Upside
QGEN Qiagen	2.30	Hold	$49.40	2.51% Upside
RGEN Repligen	2.69	Moderate Buy	$172.83	36.69% Upside

Current Analyst Ratings Breakdown

Latest RGEN, CRSP, QGEN, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/26/2025	QGEN Qiagen	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $53.00
6/24/2025	QGEN Qiagen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
6/24/2025	RGEN Repligen	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$150.00
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	112.28	N/A	N/A	$22.64 per share	2.14
DNLI Denali Therapeutics	$330.53M	6.13	N/A	N/A	$8.53 per share	1.64
QGEN Qiagen	$1.98B	5.42	$3.21 per share	14.99	$16.05 per share	3.00
RGEN Repligen	$634.44M	11.20	$3.16 per share	40.03	$35.21 per share	3.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
QGEN Qiagen	$83.59M	$0.40	120.83	19.59	2.45	4.68%	14.61%	8.80%	7/30/2025 (Estimated)
RGEN Repligen	-$25.51M	-$0.45	N/A	53.58	3.56	-3.93%	4.53%	3.17%	7/29/2025 (Estimated)

Latest RGEN, CRSP, QGEN, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/29/2025	Q2 2025	RGEN Repligen	$0.40	N/A	N/A	N/A	$174.62 million	N/A
5/7/2025	Q1 2025	QGEN Qiagen	$0.50	$0.55	+$0.05	$0.41	$465.66 million	$483.46 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
4/29/2025	Q1 2025	RGEN Repligen	$0.35	$0.39	+$0.04	$0.10	$163.65 million	$169.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
QGEN Qiagen	N/A	N/A	N/A	N/A	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A

Latest RGEN, CRSP, QGEN, and DNLI Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/1/2025	QGEN Qiagen		$0.25	0.52%	7/2/2025	7/3/2025	7/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
DNLI Denali Therapeutics	N/A	9.56	9.56
QGEN Qiagen	0.40	3.37	2.83
RGEN Repligen	0.27	6.79	5.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
DNLI Denali Therapeutics	92.92%
QGEN Qiagen	70.00%
RGEN Repligen	97.64%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.10%
DNLI Denali Therapeutics	12.50%
QGEN Qiagen	9.00%
RGEN Repligen	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	473	86.36 million	82.82 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
QGEN Qiagen	5,765	222.29 million	202.29 million	Optionable
RGEN Repligen	1,778	56.18 million	55.51 million	Optionable

RGEN, CRSP, QGEN, and DNLI Headlines

Recent News About These Companies

Allspring Global Investments Holdings LLC Purchases 16,421 Shares of Repligen Corporation (NASDAQ:RGEN)

June 30 at 4:47 AM | marketbeat.com

Repligen (NASDAQ:RGEN) Downgraded by Wall Street Zen to "Hold"

June 30 at 2:51 AM | americanbankingnews.com

Wall Street Zen Downgrades Repligen (NASDAQ:RGEN) to Hold

June 29 at 3:22 AM | marketbeat.com

Artemis Investment Management LLP Grows Position in Repligen Corporation (NASDAQ:RGEN)

June 27, 2025 | marketbeat.com

Oppenheimer Asset Management Inc. Boosts Position in Repligen Corporation (NASDAQ:RGEN)

June 27, 2025 | marketbeat.com

Bessemer Group Inc. Buys 4,325 Shares of Repligen Corporation (NASDAQ:RGEN)

June 26, 2025 | marketbeat.com

Repligen (NASDAQ:RGEN) Coverage Initiated at Barclays

June 26, 2025 | americanbankingnews.com

5 Insightful Analyst Questions From Repligen’s Q1 Earnings Call

June 25, 2025 | msn.com

Wealthquest Corp Takes Position in Repligen Corporation (NASDAQ:RGEN)

June 25, 2025 | marketbeat.com

Barclays Initiates Coverage of Repligen (RGEN) with Overweight Recommendation

June 24, 2025 | msn.com

Repligen (NASDAQ:RGEN) Earns Overweight Rating from Analysts at Barclays

June 24, 2025 | marketbeat.com

Repligen (NASDAQ:RGEN) Raised to Buy at Wall Street Zen

June 21, 2025 | marketbeat.com

Repligen Corporation (NASDAQ:RGEN) Shares Sold by Riverbridge Partners LLC

June 20, 2025 | marketbeat.com

Conestoga Capital Advisors LLC Purchases 32,665 Shares of Repligen Co. (NASDAQ:RGEN)

June 17, 2025 | marketbeat.com

Trust Point Inc. Trims Holdings in Repligen Co. (NASDAQ:RGEN)

June 17, 2025 | marketbeat.com

Repligen (NASDAQ:RGEN) Shares Down 3.1% - Should You Sell?

June 16, 2025 | marketbeat.com

Azzad Asset Management Inc. ADV Acquires Shares of 21,077 Repligen Co. (NASDAQ:RGEN)

June 15, 2025 | marketbeat.com

Does Repligen Corp (RGEN) Have a Strong Pricing Power?

June 13, 2025 | insidermonkey.com

Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from Analysts

June 11, 2025 | marketbeat.com

Repligen: Long-Term Growth Gem Suffers Some Setbacks

June 8, 2025 | seekingalpha.com

Congress Asset Management Co. Grows Holdings in Repligen Co. (NASDAQ:RGEN)

June 8, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Blockchain Stocks to Profit in a Decentralized World
By Chris Markoch | June 24, 2025
View 3 Blockchain Stocks to Profit in a Decentralized World

RGEN, CRSP, QGEN, and DNLI Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$48.51 -0.13 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$48.80 +0.30 (+0.61%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Denali Therapeutics NASDAQ:DNLI

$13.95 -0.04 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$14.17 +0.22 (+1.57%)

As of 06:32 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Qiagen NYSE:QGEN

$48.19 +0.13 (+0.27%)

Closing price 03:59 PM Eastern

Extended Trading

$48.94 +0.75 (+1.55%)

As of 04:57 PM Eastern

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Repligen NASDAQ:RGEN

$126.44 +2.06 (+1.66%)

Closing price 04:00 PM Eastern

Extended Trading

$126.46 +0.02 (+0.01%)

As of 04:46 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time